Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S1 is the largest and most flexible protein of the small (30S) ribosomal subunit in many Gram-negative bacteria, particularly *Escherichia coli*[2][4][5][7]. It consists of six tandem OB-fold (oligonucleotide/oligosaccharide binding) domains that expand outward from the ribosome and can stretch over 200 Å in length[2][5][6]. The N-terminal domains (D1 and D2) are responsible for ribosome binding, while the central and C-terminal domains (D3–D6) mediate binding to single-stranded regions of mRNA[6]. S1 is essential for cell viability and facilitates the binding and unfolding of structured or weakly recognized mRNAs at the ribosome to promote translation initiation, especially for mRNAs with complex 5′ UTRs or weak Shine–Dalgarno sequences[1][3][9]. It acts as an RNA chaperone, melting secondary structures such as pseudoknots to allow for proper mRNA accommodation and initiation codon placement in the ribosome decoding center[1][3]. Beyond translation, S1 participates in other cellular processes, including transcription recycling, trans-translation (ribosome rescue), and bacteriophage Qβ replication as a host factor[3][5][6]. S1’s unique features—essentiality, flexible structure, and RNA-unfolding activity—make it a fundamental bacterial protein, but it is not currently a drug target or clinical biomarker.
Not applicable, as there are no known drugs or experimental compounds with validated direct action on S1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S1 (S1).